FY2025 EPS Forecast for Disc Medicine Increased by Analyst

Disc Medicine, Inc. (NASDAQ:IRON) – Investment analysts at Cantor Fitzgerald upped their FY2025 earnings per share estimates for Disc Medicine in a note issued to investors on Wednesday, March 5th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings per share of ($4.59) for the year, up from their prior forecast of ($5.24). The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share.

A number of other research analysts also recently weighed in on IRON. Wedbush restated an “outperform” rating and issued a $90.00 price target (up from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. TD Cowen began coverage on Disc Medicine in a research note on Thursday, February 27th. They issued a “buy” rating for the company. Scotiabank raised their price target on Disc Medicine from $73.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, March 3rd. Morgan Stanley restated an “overweight” rating and issued a $85.00 price target on shares of Disc Medicine in a research note on Friday. Finally, Stifel Nicolaus raised their price target on Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research note on Friday, January 24th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Disc Medicine presently has an average rating of “Buy” and a consensus price target of $89.10.

Disc Medicine Stock Performance

NASDAQ:IRON opened at $55.67 on Friday. The company has a market cap of $1.66 billion, a PE ratio of -13.99 and a beta of 0.73. Disc Medicine has a 52-week low of $25.60 and a 52-week high of $68.86. The stock has a 50-day simple moving average of $57.33 and a 200 day simple moving average of $55.75.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.08.

Institutional Trading of Disc Medicine

Several hedge funds have recently added to or reduced their stakes in IRON. Sterling Capital Management LLC lifted its holdings in Disc Medicine by 798.4% during the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock worth $36,000 after purchasing an additional 503 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Disc Medicine in the 4th quarter valued at $40,000. Tower Research Capital LLC TRC raised its holdings in Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock valued at $52,000 after acquiring an additional 266 shares in the last quarter. Quest Partners LLC acquired a new position in Disc Medicine in the 3rd quarter valued at $131,000. Finally, Quantbot Technologies LP acquired a new position in Disc Medicine in the 3rd quarter valued at $146,000. 83.70% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Disc Medicine

In related news, CEO John D. Quisel sold 12,791 shares of Disc Medicine stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $66.01, for a total transaction of $844,333.91. Following the completion of the sale, the chief executive officer now directly owns 72,065 shares of the company’s stock, valued at approximately $4,757,010.65. This trade represents a 15.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Pamela Stephenson sold 3,137 shares of Disc Medicine stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $171,217.46. Following the sale, the insider now directly owns 69,529 shares of the company’s stock, valued at approximately $3,794,892.82. The trade was a 4.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 74,080 shares of company stock worth $4,523,520. 4.24% of the stock is owned by company insiders.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.